ANGO
AngioDynamics, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Fri, Nov. 11, 6:41 AM
    • Cellect Biotechnology (NASDAQ:APOP) initiated with Buy rating and $10 (163% upside) price target by Rodman & Renshaw.
    • Amedica (NASDAQ:AMDA) initiated with Buy rating and $5 (585% upside) price target by Maxim Group.
    • Vanda Pharmaceuticals (NASDAQ:VNDA) initiated with Buy rating and $24 (45% upside) price target by Aegis Capital.
    • Inovio Pharmaceuticals (NYSEMKT:INO) initiated with Buy rating and $12 (54% upside) price target by Aegis Capital.
    • Array Biopharma (NASDAQ:ARRY) initiated with Outperform rating and $10 (49% upside) price target by Cowen & Company.
    • AngioDynamics (NASDAQ:ANGO) initiated with Buy rating and $19 (15% upside) price target by Cantor Fitzgerald.
    • Ocera Therapeutics (NASDAQ:OCRX) initiated with Buy rating and $8 (227% upside) price target by Aegis Capital.
    | Fri, Nov. 11, 6:41 AM
  • Wed, Oct. 5, 11:01 AM
    | Wed, Oct. 5, 11:01 AM
  • Wed, Oct. 5, 6:11 AM
    • AngioDynamics (ANGO) FQ1 results: Revenues: $88.1M (+5.1%); Operating Income: $3.6M; Net Income: $1.3M (+262.5%); EPS: $0.04; Non-GAAP EPS: $0.17 (+54.5%); Quick Assets: $39.1M (+15.0%); CF Ops: $7.4M (+57.4%).
    • FY2017 Guidance: Revenue: $355M - 360M; Non-GAAP EPS: $0.62 - 0.65; FCF: >$30M.
    | Wed, Oct. 5, 6:11 AM
  • Wed, Oct. 5, 6:01 AM
    • AngioDynamics (NASDAQ:ANGO): FQ1 EPS of $0.17 beats by $0.04.
    • Revenue of $88.1M (+5.2% Y/Y) beats by $2.01M.
    • Press Release
    | Wed, Oct. 5, 6:01 AM
  • Tue, Oct. 4, 5:30 PM
    | Tue, Oct. 4, 5:30 PM | 4 Comments
  • Tue, Aug. 2, 9:17 AM
    | Tue, Aug. 2, 9:17 AM | 3 Comments
  • Mon, Jul. 25, 10:38 AM
    • AngioDynamics (ANGO -0.2%) appoints Michael Greiner as EVP and Chief Financial Officer effective August 16. He joins the firm from cloud-based enterprise platform provider Extreme Reach where he was responsible for all finance and human resource operations.
    | Mon, Jul. 25, 10:38 AM
  • Wed, Jul. 13, 7:15 AM
    • AngioDynamics (ANGO) FQ4 results: Revenues: $93.4M (+2.8%); R&D Expense: $6.9M (-5.5%); SG&A: $28.1M (-1.1%); Operating Loss: ($2.1M) (-362.5%); Net Loss: ($44M); Loss Per Share: ($1.21); Non-GAAP EPS: $0.19 (+35.7%); CF Ops: $18.5M (+71.3%).
    • FY2016 results: Revenues: $353.7M (-0.9%); R&D Expense: $25.1M (-6.7%); SG&A: $114.1M (+1.5%); Operating Income: $0.7M (+124.1%); Net Loss: ($44.5M); Loss Per Share: ($1.23); Non-GAAP EPS: $0.58 (unch); Quick Assets: $34M (+69.2%); CF Ops: $45.2M (+72.5%).
    • FQ1 Guidance: Revenue: $84M - 87M; Non-GAAP EPS: $0.11 - 0.14.
    • FY2017 Guidance: Revenue: $355M - 360M; Non-GAAP EPS: $0.62 - 0.65.
    | Wed, Jul. 13, 7:15 AM
  • Wed, Jul. 13, 6:03 AM
    • AngioDynamics (NASDAQ:ANGO): FQ4 EPS of $0.19 beats by $0.03.
    • Revenue of $93.37M (+2.7% Y/Y) beats by $4.96M.
    • Press Release
    | Wed, Jul. 13, 6:03 AM
  • Tue, Jul. 12, 5:30 PM
  • Wed, Apr. 20, 10:52 AM
    • In a regulatory filing, AngioDynamics (ANGO +0.3%) reports that VP and interim Chief Financial Officer Michael Trimarchi intends to resign on May 13 to accept another position.
    • EVP and Chief Commercial Officer John Soto will be terminated effective May 2. The company has no current plans to backfill the position as CEO James Clemmer will oversee the commercial organization.
    | Wed, Apr. 20, 10:52 AM
  • Fri, Apr. 8, 6:47 AM
    • AngioDynamics (ANGO) FQ3 results: Revenues: $87.4M (+0.9%); R&D Expense: $5.8M (-15.9%); SG&A: $27.1M (+3.0%); Operating Income: $2.7M (+126.5%); Net Income: $0.6M (+114.0%); EPS: $0.02 (+116.7%); Non-GAAP EPS: $0.15 (+25.0%); Quick Assets: $23.6M (+17.4%).
    • FQ4 Guidance: Revenue: $87M - 90M; Adjusted EPS: $0.14 - 0.18.
    • FY2016 Guidance: Revenue: $347M - 350M; Adjusted EPS: $0.54 - 0.58; Cash Flow: $30M.
    | Fri, Apr. 8, 6:47 AM
  • Thu, Apr. 7, 4:03 PM
    • AngioDynamics (NASDAQ:ANGO): FQ3 EPS of $0.15 beats by $0.01.
    • Revenue of $87.4M (+0.9% Y/Y) beats by $2.33M.
    | Thu, Apr. 7, 4:03 PM
  • Wed, Apr. 6, 5:35 PM
  • Fri, Jan. 8, 6:49 AM
    • AngioDynamics (ANGO) FQ2 results: Revenues: $89.2M (-3.1%); R&D Expense: $6.2M (+1.6%); SG&A: $28.7M (-1.0%); Operating Income: $1.3M (-71.7%); Net Loss: ($0.4M) (-130.8%); Loss Per Share: ($0.01) (-125.0%); Non-GAAP EPS: $0.14 (-17.6%); Quick Assets: $20.6M (+2.5%).
    • FY2016 Guidance: Net Sales: $353M - 359M; Adjusted EPS: $0.59 - 0.63.
    • FQ3 Guidance: Net Sales: $84M - 87M; Adjusted EPS: $0.10 - 0.14.
    | Fri, Jan. 8, 6:49 AM
  • Thu, Jan. 7, 4:06 PM
    • AngioDynamics (NASDAQ:ANGO): FQ2 EPS of $0.14 in-line.
    • Revenue of $89.2M (-3.2% Y/Y) beats by $0.53M.
    | Thu, Jan. 7, 4:06 PM